|
In Vitro Activity of the New Azole BAL4815 and other Antifungal Agents against Candida Bloodstream Isolates (click for details) |
|
|
|
In Vitro Activity of the New Azole Isavuconazole (BAL 4815) Compared with Six other Antifungal Agents against 155 Cryptococcus neoformans Isolates from Cuba (click for details) |
|
|
|
Impact of a Caspofungin (CAS) Restriction Policy on Appropriateness of Use and the Financial Implications in a Large Tertiary Hospital.
(click for details) |
|
|
|
Body Mass Index (BMI) Significantly Increased with Macrolide Treatment in Patients with Chronic Necrotizing Pulmonary Aspergillosis.
(click for details) |
|
|
|
Activity In Vitro of 27 Combinations of Licensed Antifungal Agents against Scedosporium apiospermum (Sa) and Scedosporium prolificans (Sp).
(click for details) |
|
|
|
Cross Reactivity in the Platelia Aspergillus Galactomannan Antigenemia Assay Caused by Histoplasmosis.
(click for details) |
|
|
|
Efficacy of New Polymeric Guandine against Yeasts and Filamentous Fungi.
(click for details) |
|
|
|
Micafungin (MCF) Alone or in Combination with Other Licensed Antifungal Therapy (OLAT) in Bone Marrow Transplant (BMT) Recipients with Invasive Aspergillosis (IA). (click for details) |
|
|
|
Evaluation of the Efficacy of Liposomal Amphotericin B (L-AmB) or Caspofungin (CAS) in the Treatment of Experimental Candida albicans Catheter Infection (CI) Using the Antifungal-Lock Technique (ALT).
(click for details) |
|
|
|
Gliotoxin Induces Concentration-Dependent Apoptosis in Alveolar Epithelial Type II Pneumocytes.
(click for details) |
|
|
